Role of macrophage in nanomedicine-based disease treatment

Abstract

Macrophages are a major component of the immunoresponse. Diversity and plasticity are two of the hallmarks of macrophages, which allow them to act as proinflammatory, anti-inflammatory, and homeostatic agents. Research has found that cancer and many inflammatory or autoimmune disorders are correlated with activation and tissue infiltration of macrophages. Recent developments in macrophage nanomedicine-based disease treatment are proving to be timely owing to the increasing inadequacy of traditional treatment. Here, we review the role of macrophages in nanomedicine-based disease treatment. First, we present a brief background on macrophages and nanomedicine. Then, we delve into applications of macrophages as a target for disease treatment and delivery systems and summarize the applications of macrophage-derived extracellular vesicles. Finally, we provide an outlook on the clinical utility of macrophages in nanomedicine-based disease treatment.

Unleashing the Potential of Oral Deliverable Nanomedicine in the Treatment of Inflammatory Bowel Disease

“… 49 Macrophages, serving as initial responders in the innate immune system to nanomaterials, emerge as a focal point for cell-targeting strategies in nano-based therapies for IBD. 50 Numerous molecular targets associated with macrophages, particularly saccharide receptors such as the lectin receptor macrophage galactose-type C-type lectin (MGL), mannose receptors, and dectin-1, have been explored for NP targeting. 11 , 12 , 36 , 37 …”

Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy

“…The macrophage membrane surface abounds with lipids and proteins, thus presenting an opportunity for loading nanodrugs through chemical conjugation or physical adsorption [ 72 ]. The drug loading method can effectively prolong the drug circulation time, specifically by targeting deeper regions of the tumour and augmenting the effectiveness of the anticancer medication [ 72 , 82 ]. In a recent study, macrophage-encapsulated mesoporous silica cocoon materials were developed to deliver DOX to 4T1 tumours [ 83 ].…”